Clinical and Mycological Clearance of Vulvovaginal Candidiasis With Fluconazole of Kit 2, NACO, GOI

Abstract

Background: Candida albicans, along with other closely related Candida species, are the primary causative agents of vulvovaginal candidiasis (VVC)—a multifactorial infectious disease of the lower female reproductive tract resulting in pathologic inflammation. Aims: The present study was undertaken to know the clinical and Mycological clearance of Vulvovaginal candidiasis after treatment with Fluconazole of Kit 2 of NACO. It has been carried out in the tertiary care center over a period of 18 months. Materials and methods: A total of 100 patients of Clinically and Mycologically verified Candidiasis cases were included in the study and given Kit 2 of NACO and invited for follow up visit at 7 days after the initial visit and second follow up visit at 14 days. In follow up visit women were examined and vaginal swab was taken for smear. Results: Clinical efficacy assessment – at short term follow up visit complete cure occur in 80% short term cases and at long term follow up visit 76% were cured. Mycological efficacy assessment – at short term follow up visit complete cure occur in 93% short term cases and at long term follow up visit 86% were cured. Overall assessment - Excellent in 73 cases (73%), fair in 13 cases (13%), poor in 7 cases (7%), recurrence in 7 cases (7%). Conclusion: It can be said that fluconazole 150mg single dose of Kit 2 of NACO is safe and effective drug used in cases of Vulvovaginal candidiasis and achieves good control and cure in most of the patients.